CompletedNot Applicable

JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)

South Korea299 participantsStarted 2024-03-29

Plain-language summary

The primary objective is to monitor the safety profile of JARDIANCE® in Korean patient with chronic kidney disease (CKD) in routine clinical practice. The secondary objective is to monitor the efficacy of JARDIANCE® by evaluating changes in urine albumin-creatinine ratio (UACR) after 12 and/or 24 weeks of treatment.

Who can participate

Age range

19 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≧19 years at enrolment * Patients diagnosed with CKD * Patients with CKD starting JARDIANCE® for the first time in accordance with the approved label in Korea * Patients who have provided informed consent and signed the data release consent form Exclusion Criteria: * Patients with previous exposure to JARDIANCE® * Patients with hypersensitivity to empagliflozin or to any of the excipients * Patients with type 1 diabetes * Patients with history of Diabetic Ketoacidosis (DKA) * Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption * Patients who are pregnant or are breastfeeding or who plan to become pregnant during the study period

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of Participants With Adverse Events (AEs)

Timeframe: Up to 337 days.

Number of Participants With Serious Adverse Event (SAEs)

Timeframe: Up to 337 days.

Number of Participants With Non-serious Adverse Events

Timeframe: Up to 337 days.

Number of Participants With Adverse Drug Reaction (ADR)s

Timeframe: Up to 337 days.

Number of Participants With Serious Adverse Drug Reactions

Timeframe: Up to 337 days.

Number of Participants With Unexpected Adverse Events

Timeframe: Up to 337 days.

Number of Participants With Adverse Events of Special Interest (AESIs)

Timeframe: Up to 337 days.

Trial details

NCT IDNCT06287073

SponsorBoehringer Ingelheim

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-04-30

Results submitted2026-04-29

View on ClinicalTrials.gov More Kidney Disease, Chronic trials

Plain-language summary

Who can participate

Age range

19 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Number of Participants With Adverse Events (AEs)

Timeframe: Up to 337 days.

Number of Participants With Serious Adverse Event (SAEs)

Timeframe: Up to 337 days.

Number of Participants With Non-serious Adverse Events

Timeframe: Up to 337 days.

Number of Participants With Adverse Drug Reaction (ADR)s

Timeframe: Up to 337 days.

Number of Participants With Serious Adverse Drug Reactions

Timeframe: Up to 337 days.

Number of Participants With Unexpected Adverse Events

Timeframe: Up to 337 days.

Number of Participants With Adverse Events of Special Interest (AESIs)

Timeframe: Up to 337 days.